T helper 2 cells regulate inflammatory responses to helminth infections while also mediating pathological processes of asthma and allergy. IL-4 promotes Th2 development by inducing the expression of the GATA3 transcription factor, and the Th2 phenotype is stabilized byaGATA3-dependentautoregulatoryloop.Inthisstudy, we found that type I IFN (IFN-a/b) blocked human Th2 development and inhibited cytokine secretion from committed Th2 cells. This negative regulatory pathway was operative in human but not mouse CD4 + T cells and was selective to type I IFN, as neither IFN-g nor IL-12 mediated such inhibition. IFN-a/b blocked Th2 cytokine secretion through the inhibition of GATA3 during Th2 development and in fully committed Th2 cells. Ectopic expression of GATA3 via retrovirus did not overcome IFN-a/b-mediated inhibition of Th2 commitment. Thus, we demonstrate a novel role for IFN-a/b in blocking Th2 cells, suggesting its potential as a promising therapy for atopy and asthma. The Journal of Immunology, 2010, 185: 813-817.
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D4
+ Th2 cells regulate both humoral and cellmediated inflammatory responses to helminth pathogens as well as toxins and other foreign soluble molecules (1) . In genetically predisposed individuals, Th2 cells also mediate atopic responses to normally innocuous materials, such as animal dander, pollens, and pollutants. Th2 cells mediate these processes through the selective secretion of a subset of cytokines that include IL-4, IL-5, IL-13, and, in some cases, IL-9 and IL-10 (2). Together, these cytokines lead to a cascade of events that culminate in driving inflammation at sites of allergen contact, such as the lungs in cases of allergic asthma.
Various signals contribute to a Th2 environment, such as thymic stromal lymphopoietin, OX40 ligand, Notch (3), and IL-25 (4); however, IL-4 remains the key signal that directly drives Th2 commitment. IL-4R signaling promotes STAT6 recruitment and phosphorylation (5), which ultimately regulates induction of GATA3 transcription (6) . GATA3 is a member of the 2-zinc finger GATA-binding family of transcription factors, and its expression is critical for both T cell thymic development and Th2 commitment (7) . Once induced by IL-4, the GATA3 protein positively regulates Th2 cytokine gene expression and negatively regulates various aspects of Th1 commitment, such as inhibiting the expression of the IL-12Rb2 subunit (8) . Further, GATA3 positively regulates its own expression through an autoactivation loop, thereby maintaining Th2 stability in the absence of further IL-4 signaling (9, 10). The inherent stability of Th2 cells poses a significant challenge to treating allergic diseases. However, in this study, we have found that type I IFN (IFN-a/b) potently inhibits IL-4-driven Th2 commitment in human CD4
+ T cells and destabilizes the Th2 phenotype by inhibiting GATA3 expression. Considering that IFN-a/b is used routinely to treat various diseases including multiple sclerosis and hepatitis C, we propose that IFN-a/b may represent a novel and readily available therapy for atopic conditions, such as allergic asthma.
Materials and Methods
Human subjects
Peripheral blood was collected from healthy adult donors, and informed consent was obtained from each donor according to the guidelines approved by the Institutional Review Board at University of Texas Southwestern Medical Center (Dallas, TX).
T cell cultures
Naive CD4 + /CD45RA + T cells were purified (.90%) from buffy coats either by flow cytometric sorting or by magnetic bead separation (BD Biosciences, San Jose, CA) as previously described (11) Cytokines and Abs were used at the following concentrations: anti-CD3 (5.0 mg/ml), anti-CD28 (5.0 mg/ml), IL-2 (50 U/ml), IL-4 (20 ng/ml), IL-12 (10 ng/ml), IFN-g (5 ng/ml), IFN-a (1000 U/ml), IFN-b (1000 U/ml), IL-29 (100 ng/ml), anti-IL-4 (2 mg/ml), anti-IL-12 (5 mg/ml), anti-IFN-g (5 mg/ml), and anti-IFNAR2 (2 mg/ml). Cells were cultured for either 7 d or restimulated with anti-CD3/anti-CD28 with various cytokine conditions for an additional 7 d prior to analysis. expressed on Th2 cells [CRTH2])-Alexa 647, pY641-STAT6, and streptavidinPerCP (BD Biosciences); hSTAT6 (Santa Cruz Biotechnology, Santa Cruz, CA); and hIL-4-FITC, hIL-5-PE, hIL-13-allophycocyanin (Biolegend, San Diego, CA). Data were collected on an LSR II or FACSCalibur (BD Biosciences) and processed using FlowJo (Tree Star, Ashland, OR).
Quantitative real-time PCR analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) or PicoPure Kit (Arcturus, Molecular Devices, Sunnyvale, CA) according to the manufacturer's instructions followed by reverse transcription. The resultant cDNA was subjected to quantitative PCR analysis with SYBR Green Master Mix (Stratagene, La Jolla, CA) on an ABI7300 real-time thermocycler (Applied Biosystems, Foster City, CA). Human GAPDH was used as a reference. Relative changes in mRNA expression were calculated by the 2 2DDCT method (13) , and all treatment groups were referenced to the neutralized control. The primers used to detect mRNA transcripts are as follows: hGATA3: 59-AGGGACGTCCTGTGCGAACT-39 and 59-GGTCTGGAT-GCCTTCCTTCTTCAT-39; hT-bet, 59-CGTCCAACAATGTGACCCA-G-39 and 59-GCAGTCACGGCAATGAACTG-39; and hGAPDH, 59-CTGCACCACCAACTGCTTAGC-39 and 59-TCATGTTCTGGAGAGC-CCCG-39.
Quantification of secreted cytokines
Standard cytokine ELISAs were performed as previously described (14) . Alternatively, multiple cytokine concentrations were quantified by Cytometic Bead Array (BD Biosciences) or Meso Scale Discovery platform according to the manufacturer's instructions (Meso Scale Discovery, Gaithersburg, MD).
Retroviral transduction
Retroviral supernatants were generated by transfection of the Phoenix amphotropic cell line as described (10) . Purified CD4 + /CD45RA + cells were activated with plate-bound anti-CD3/anti-CD28 in complete IMDM with IL-2, IL-4, anti-IL-12, and anti-IFN-g for 7 d. The cells were then reactivated with anti-CD3/anti-CD28 plus IL-2 and transduced with retroviral constructs expressing either GFP only (GFPRV) or hGATA3 (GATA3-GFP) (10) . At day 14, transduction efficiency averaged between 3 and 5%, and GFP + cells were sorted to .90% purity. These GFP + cells were then reactivated with anti-CD3/anti-CD28 plus IL-2 in the presence or absence of IFN-a.
Statistical analysis
All bar graphs are shown as mean 6 SEM. Statistical analysis was performed by one-way ANOVA using Prism software (GraphPad, San Diego, CA). All p , 0.05 were considered significant.
Results and Discussion
Selective inhibition of human Th2 development by IFN-a/b IL-4 is a critical regulator of Th2 development, and the downstream signaling events in this pathway dominate over the effects of other Th1-inducing signals, such as IFN-g and IL-12. Although early reports suggested that IFN-a/b could decrease baseline Th2 cytokine secretion in naive human CD4 + T cells (15, 16) , the role of IFN-a during Th2 priming in response to IL-4 has not been investigated in human cells. Previous studies with mouse DO11.10 T cells ruled out IFN-a/b as a negative regulator of Th2 commitment (17, 18) . Indeed, we confirmed these previous observations by demonstrating that IFN-a does not inhibit IL-4-driven Th2 development in murine OT-II transgenic T cells (Supplemental Fig. 1 ). However, in the current study, we tested the role of IFN-a/b in regulating human Th2 development by activating purified naive human CD4 + / CD45RA + T cells with plate-bound anti-CD3/anti-CD28 in the presence of cytokines or neutralizing anti-cytokine Abs for 7 d. Cells were then restimulated and assessed for cytokine production. IL-4 potently induced Th2 development by promoting high levels of IL-4 expression (Fig. 1A, lower panel) , as well as IL-4 and IL-5 secretion (Fig. 1B) . Moreover, IL-12, but not IFN-a, promoted Th1 commitment as revealed by high levels of IFN-g expression (Fig. 1A, upper panel) . Neither IL-12 nor IFN-g inhibited IL-4 expression (Fig. 1A , lower panel, 1B, upper panel), whereas IL-12 did inhibit IL-5 secretion by ∼50% (Fig. 1B, lower panel) . In contrast, we found that IFN-a markedly blocked IL-4-driven Th2 development in human CD4 + T cells (Fig. 1A, lower panel, 1B) . This inhibition was specific to Th2 cells, as IFN-a did not block IL-12-mediated Th1 development (Fig. 1A, upper panel) , and IFN-a consistently inhibited Th2 development in cells isolated from each of 10 healthy adult donors (Fig. 1C) . IFN-a did not attenuate proliferation during priming, suggesting that IFN-a/b did not interfere with Th2 commitment by inhibiting Th2 cell expansion (Supplemental Fig. 2 ). Finally, both IFN-a and IFN-b blocked Th2 development in a dose-dependent manner (Supplemental Fig. 3 ), suggesting that Th2 cross regulation in human CD4 + T cells is a general property of IFN-a/b signaling. In humans, the PGD 2 receptor, CRTH2, is selectively expressed on Th2 cells (19) and is induced by IL-4 during Th2 development (20) . We assessed the expression of CRTH2 in response to cytokine activation during Th2 commitment in human CD4 + T cells. IL-4 promoted the development of cells expressing CRTH2; however, IFN-a markedly blocked IL-4-driven CRTH2 expression (Fig. 1D) . A recent report suggested that IL-28/29 (IFN-l, type III IFN) could inhibit human Th2 cells (21) . We compared IL-29 (IFN-l1) with IFN-a and observed a modest decrease in IL-4-driven CRTH2 expression in response to IL-29 that was not significantly different compared with treatment with IL-4 alone (Fig. 1D , compare conditions 2 and 6). However, we found that IFN-a significantly blocked IL-4-mediated CRTH2 expression compared with IL-29 (Fig.  1D) . Therefore, IFN-a/b inhibits both Th2 cytokine secretion and expression of the inflammatory receptor CRTH2 that mediates recruitment and cytokine secretion from committed Th2 cells (22) . Collectively, these data demonstrate a unique and species-specific inhibition of human Th2 development by IFN-a/b.
IFN-a/b destabilizes committed human Th2 cells by repressing GATA3
IL-4 regulates Th2 commitment via activation of STAT6, which drives expression of the Th2-specific transcription factor GATA3 (5, 6, 23). GATA3 stabilizes the Th2 phenotype by a feedback loop that uncouples the requirement for further IL-4 signaling (9, 10). We tested the ability of IFN-a to disrupt the stability of committed Th2 cells by first activating naive T cells for 1 wk with IL-4 ( Fig. 2) . These cells were then reactivated for an additional 7 d with either IL-4, anti-IL-4, IFN-a, or IL-4 plus IFN-a followed by analysis of Th2 cytokine production. IL-4 efficiently promoted the development of Th2 cells, and, as expected, their stability was maintained during secondary culture regardless if the cells were activated with additional IL-4 or with anti-IL-4 ( Fig. 2A, conditions 1-3) . However, IFN-a markedly inhibited Th2 cytokine expression during secondary activation even in the presence of additional IL-4. Further, IFN-a inhibited IL-4 secretion to levels observed in non-Th2 cells cultured under neutralizing conditions for 2 consecutive wk (Fig. 2B) .
A recent study by Löhning and colleagues (24) demonstrated that a combination of IL-12 plus IFN-g and IFN-a could promote IFN-g secretion from fully committed murine Th2 cells and give rise to IL-4/IFN-g dual cytokine-secreting cells. However, we found that in human, IFN-a alone suppressed IL-4 secretion both during priming (Fig. 1) and after secondary activation (Fig. 2) even in the absence of IL-12. Moreover, we found that in human Th2 cells, the combination of IFN-g plus IFN-a plus IL-12 only marginally increased IFN-g secretion during secondary priming (Supplemental Fig. 4) . Thus, in human CD4 + T cells, IFN-a suppresses Th2 commitment and stability and is dominant over the Th2-promoting signal of IL-4. Importantly, IFN-a does not promote significant IFN-g secretion either during priming or during secondary redirection, making IFN-a an attractive therapeutic candidate for atopic diseases.
GATA3 is required for Th2 cell stability and cytokine production. CD4
+ cells from mice with a T cell-specific deletion of GATA3 produce increased levels of IFN-g but greatly reduced levels of IL-4, IL-5, and IL-13 (7) . Additionally, the deletion of GATA3 specifically in Th2 cells significantly impairs their ability to produce these cytokines (7, 25) . Based on these observations, we tested the ability of IFN-a to modulate the induction of GATA3 by IL-4 (Fig. 3) . IL-4 induced GATA3 mRNA in naive hCD4 + T cells (Fig. 3A , compare conditions 1 and 2). However, cells cultured with IFN-a showed significantly reduced GATA3 transcript levels (Fig. 3A, conditions 3 and  4) . The block in GATA3 mRNA also resulted in a significant inhibition of IL-4-induced GATA3 protein by IFN-a (Fig. 3B,  3C ). As previously reported (26, 27) , naive CD4 + T cells expressed low levels of GATA3 that were induced by TCR activation and further elevated in response to IL-4 (Fig. 3C,  conditions 1-3 ). In line with the observed decrease in GATA3 mRNA (Fig. 3A) , IFN-a significantly inhibited IL-4-induced GATA3 protein expression that was not observed in response to either IL-12 or IFN-g (Fig. 3C) . Because we have demonstrated that IFN-a inhibits the development of CRTH2 + cells (Fig. 1D) , it is not surprising that IFN-a controls GATA3 as well, considering that GATA3 has been shown to control the expression of CRTH2 (28) . Thus, the ability of IFN-a to regulate a key Th2 transcription factor correlates with its ability to regulate CRTH2 and Th2 cytokine expression.
A variety of GATA-binding proteins, such as Runx, Fog, and T-bet, have been shown to inhibit the transcriptional regulatory activity of GATA family members, including GATA3. We tested whether any of the select members of these GATAbinding factors were induced by IFN-a during priming. However, we found that neither Runx3, Fog1 (data not shown), nor T-bet (Fig. 3D) were significantly induced by IFN-a during Th2 development, suggesting a novel negative regulatory mechanism for GATA3 inhibition.
IFN-a/b overrides GATA3-mediated Th2 stability
Because IFN-a limits cytokine production from committed Th2 cells, we considered whether IFN-a bypassed IL-4 signaling and inhibited GATA3 expression directly. Although induction of GATA3 by IL-4 depends upon the activation of STAT6 (23), we tested this early signaling event and found IFN-a (2˚conditions) . A, Cells were stimulated with PMA plus ionomycin for 6 h, and IL-4, IL-5, and IL-13 were measured by intracellular staining. B, Cells were stimulated with PMA plus ionomycin for 48 h, and IL-4 was quantified by ELISA from the culture supernatants. *p , 0.05 compared with IL-4 (A and B, condition 3) .
that IFN-a did not significantly alter acute IL-4-driven STAT6 phosphorylation (Supplemental Fig. 5 ). Thus, we determined if IFN-a could inhibit GATA3 protein levels in committed Th2 cells that have already upregulated the protein (Fig. 4A) . Polarization of naive T cells with IL-4 for 7 d led to a stable increase in GATA3 protein levels (Fig. 4A, conditions 1-3) . However, IFN-a markedly inhibited GATA3 protein expression (Fig. 4A , conditions 4 and 5), and these data strongly suggest that IFN-a destabilizes hTh2 cells by directly interfering with GATA3 expression.
GATA3 is considered a master regulator of Th2 development based on its ability to promote Th2 commitment when ectopically expressed in cells under various counterregulatory situations. The GATA3 feedback loop was originally discovered when cells transduced with GATA3RV subsequently upregulated the endogenous GATA3 mRNA (9) . We hypothesized that ectopic expression of GATA3 in human Th2 cells would elevate GATA3 protein levels and thereby reverse the inhibition normally mediated by IFN-a. To test this hypothesis, we expressed GATA3 in human Th2 cells via retroviral transduction (Fig. 4) . GFP + cells were reactivated for 3 d, and the culture supernatants were analyzed for IL-5 and IL-13 (Fig. 4B) . As expected, the levels of both cytokines increased significantly in cells transduced with GATA3-GFP compared with the control retrovirus (Fig. 4B) . The addition of IFN-a to the culture inhibited the secretion of both IL-5 and IL-13 from cells transduced with empty retrovirus as well as in cells transduced with GATA3-GFP. Purified GFP + cells were cultured for 7 d, at which time the cells were washed, reactivated, and analyzed for cytokine secretion (Fig. 4C) . Again, addition of IFN-a to the culture inhibited the secretion of Th2 cytokines even in cells ectopically expressing GATA3. Thus, IFN-a is able to overcome ectopic expression of GATA3 and suppress the secretion of Th2 cytokines. To confirm that GATA3 was actually expressed in the transduced cells, we analyzed GATA3 protein levels by intracellular staining at day 5 following sorting (Fig. 4D) . Indeed, GATA3 protein levels increased in cells transduced with GATA3-GFP compared with the GFPRV control. However, IFN-a treatment reduced GATA3 protein levels in cells transduced with either the empty retrovirus or with GATA3-expressing retrovirus. IFN-a treatment did not affect the retroviral mRNA levels (data not shown), further supporting the conclusion that IFN-a inhibits GATA3 protein levels.
In summary, we demonstrate a novel function for type I IFN to block Th2 development and destabilize committed Th2 cells via inhibition of GATA3. This function is lacking in mice but may be important for ensuring proper differentiation of CD4 + T cells activated during viral infections in humans. As IFN-a/b has already been demonstrated to inhibit the development of Th17 but not Th1 cells (12, 29, 30 ), IFNa/b may restrict alternate differentiation pathways for newly activated CD4 + T cells. Further, both Th2 and Th17 responses have been proposed to contribute to the pathology of allergic diseases (31, 32) . Thus, because IFN-a/b inhibits both Th17 and Th2 pathways but does not promote Th1 cytokine expression, we propose that IFN-a/b may be useful as a therapy for the treatment of allergies and asthma.
